About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

New Target for Alzheimer's Disease Drugs Discovered

by Bidita Debnath on October 21, 2017 at 11:44 PM
Font : A-A+

New Target for Alzheimer's Disease Drugs Discovered

Alzheimer's is the sixth leading cause of death in the United States. Those with Alzheimer's live an average of eight years after their symptoms become noticeable to others, but survival can range from four to 20 years, depending on age and other health conditions.

A probe invented at Rice University that lights up when it binds to a misfolded amyloid beta peptide -- the kind suspected of causing Alzheimer's disease -- has identified a specific binding site on the protein that could facilitate better drugs to treat the disease.

Advertisement


Even better, the lab has discovered that when the metallic probe is illuminated, it catalyzes oxidation of the protein in a way they believe might keep it from aggregating in the brains of patients.

The study done on long amyloid fibrils backs up computer simulations by colleagues at the University of Miami that predicted the photoluminescent metal complex would attach itself to the amyloid peptide near a hydrophobic (water-avoiding) cleft that appears on the surface of the fibril aggregate. That cleft presents a new target for drugs.
Advertisement

Finding the site was relatively simple once the lab of Rice chemist Angel Martí used its rhenium-based complexes to target fibrils. The light-switching complex glows when hit with ultraviolet light, but when it binds to the fibril it becomes more than 100 times brighter and causes oxidation of the amyloid peptide.

"It's like walking on the beach," Marti said. "You can see that someone was there before you by looking at footprints in the sand. While we cannot see the rhenium complex, we can find the oxidation (footprint) it produces on the amyloid peptide.

"That oxidation only happens right next to the place where it binds," he said. "The real importance of this research is that allows us to see with a high degree of certainty where molecules can interact with amyloid beta fibrils."

The study appears in the journal Chem. "We believe this hydrophobic cleft is a general binding site (on amyloid beta) for molecules," Martí said. "This is important because amyloid beta aggregation has been associated with the onset of Alzheimer's disease. We know that fibrillar insoluble amyloid beta is toxic to cell cultures. Soluble amyloid oligomers that are made of several misfolded units of amyloid beta are also toxic to cells, probably even more than fibrillar.

"There's an interest in finding medications that will quench the deleterious effects of amyloid beta aggregates," he said. "But to create drugs for these, we first need to know how drugs or molecules in general can bind and interact with these fibrils, and this was not well-known. Now we have a better idea of what the molecule needs to interact with these fibrils."

When amyloid peptides fold properly, they hide their hydrophobic residues while exposing their hydrophilic (water-attracting) residues to water. That makes the proteins soluble, Martí said. But when amyloid beta misfolds, it leaves two hydrophobic residues, known as Valine 18 and Phenylalanine 20, exposed to create the hydrophobic cleft.

"It's perfect, because then molecules with hydrophobic domains are driven to bind there," Martí said. "They are compatible with this hydrophobic cleft and associate with the fibril, forming a strong interaction."

If the resulting oxidation keeps the fibrils from aggregating farther into the sticky substance found in the brains of Alzheimer's patients, it may be the start of a useful strategy to stop aggregation before symptoms of the disease appear.

"It's a very attractive system because it uses light, which is a cheap resource," Martí said. "If we can modify complexes so they absorb red light, which is transparent to tissue, we might be able to perform these photochemical modifications in living animals, and maybe someday in humans."

He said light activation allows the researchers to have "exquisite control" of oxidation. "We imagine it might be possible someday to prevent symptoms of Alzheimer's by targeting amyloid beta in the same way we treat cholesterol in people now to prevent cardiovascular disease," Martí said. "That would be wonderful."

Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
Memory Loss - Can it be Recovered?
International Day of Persons with Disabilities 2021 - Fighting for Rights in the Post-COVID Era
Effect of Blood Group Type on COVID-19 Risk and Severity
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Drugs Banned in India 

Recommended Reading
Risk Factors for Alzheimers Disease
Cognitively normal adults exhibiting atrophy of their temporal lobe or damage to blood vessels in .....
Inability to Recognize Familiar Smells Could Signal Alzheimers
People who have difficulty recognizing familiar smells could be experiencing an early sign of ......
Long-Term Cognitive Impairment in Hospitalized Elderly
People who had urgent hospitalization experienced cognitive decline. But, those who were never ......
Rare Disease Could Help Find Cure for Nervous-Neurologic Disorders
Single strand breaks are one of the most common types of DNA damage and could help spot other rare ....
Drug Toxicity
Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a d...
Drugs Banned in India
Several drugs are either banned or withdrawn after introduction in the market....

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use